{"id":5218,"date":"2021-11-12T12:11:39","date_gmt":"2021-11-12T09:11:39","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5218"},"modified":"2021-11-17T13:02:49","modified_gmt":"2021-11-17T10:02:49","slug":"preseco-calismasi-sonuclandi-favipiravir-covid-19-tedavisinde-etkisiz","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/preseco-calismasi-sonuclandi-favipiravir-covid-19-tedavisinde-etkisiz\/","title":{"rendered":"PRESECO \u00c7al\u0131\u015fmas\u0131 Sonu\u00e7land\u0131: Favipiravir COVID-19 Tedavisinde Etkisiz"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-107369 alignleft\" src=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2021\/11\/businesswire.png\" alt=\"\" width=\"144\" height=\"35\" \/><strong>Bula\u015f\u0131c\u0131 hastal\u0131klar i\u00e7in ila\u00e7 geli\u015ftirmeye odaklanan biyofarmas\u00f6tik \u015firketi Appili Therapeutics, hafif veya orta \u015fiddette COVID-19&#8217;un klinik tedavisinde a\u011f\u0131zdan al\u0131nan antiviral Avigan\u00ae\/Reeqonus\u2122 (favipiravir)&#8217;u de\u011ferlendiren Faz 3 PRESECO (PREventing SEvere COVID-19) \u00e7al\u0131\u015fmas\u0131n\u0131n klinik deneylerinde, kal\u0131c\u0131 klinik iyile\u015fmeye kadar olan birincil sonlanma noktas\u0131nda istatistiksel a\u00e7\u0131dan anlaml\u0131 bir fark bulunmad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/strong><\/p>\n<p>Klinik deney verilerine ili\u015fkin ek analizlerin devam etti\u011fi ifade ediliyor. Klinik ara\u015ft\u0131rmaya Amerika Birle\u015fik Devletleri, Meksika ve Brezilya&#8217;daki 38 \u00e7al\u0131\u015fma b\u00f6lgesinden hafif veya orta \u015fiddette COVID-19&#8217;lu 1231 hasta dahil edilmi\u015fti.<\/p>\n<p>Faz 3 PRESECO \u00e7al\u0131\u015fmas\u0131, hafif-orta \u015fiddette semptomlar g\u00f6steren COVID-19 hastalar\u0131nda Avigan\/Reeqonus (favipiravir)&#8217;un erken tedavideki g\u00fcvenli\u011fini ve etkinli\u011fini ara\u015ft\u0131ran \u00e7ift k\u00f6r, plasebo kontroll\u00fc, randomize, \u00e7ok merkezli, k\u00fcresel \u00fcst\u00fcnl\u00fck \u00e7al\u0131\u015fmas\u0131d\u0131r. Kat\u0131l\u0131mc\u0131lar, Amerika Birle\u015fik Devletleri, Brezilya ve Meksika&#8217;daki farkl\u0131 klinik ara\u015ft\u0131rma merkezlerinde \u00e7al\u0131\u015fmaya kaydedilmi\u015ftir. Kay\u0131t olduktan sonraki 72 saat i\u00e7inde COVID-19 testi pozitif olan, hafif-orta semptomlu hastalar \u00e7al\u0131\u015fmaya dahil edilmi\u015ftir. \u0130la\u00e7 tedavisini evde kendileri uygulayan kat\u0131l\u0131mc\u0131lar, klinik ara\u015ft\u0131rmac\u0131lar taraf\u0131ndan uzaktan izlenmi\u015flerdir.<\/p>\n<p><a href=\"https:\/\/www.businesswire.com\/news\/home\/20211112005554\/en\/Appili-Therapeutics-Provides-Update-on-Phase-3-PRESECO-Clinical-Trial-Evaluating-Avigan%C2%AEReeqonus%E2%84%A2\"><strong>Haber \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bula\u015f\u0131c\u0131 hastal\u0131klar i\u00e7in ila\u00e7 geli\u015ftirmeye odaklanan biyofarmas\u00f6tik \u015firketi Appili Therapeutics, hafif veya orta \u015fiddette COVID-19&#8217;un klinik tedavisinde a\u011f\u0131zdan al\u0131nan antiviral Avigan\u00ae\/Reeqonus\u2122 (favipiravir)&#8217;u de\u011ferlendiren Faz 3 PRESECO (PREventing SEvere COVID-19) \u00e7al\u0131\u015fmas\u0131n\u0131n klinik deneylerinde, kal\u0131c\u0131 klinik iyile\u015fmeye kadar olan birincil sonlanma noktas\u0131nda istatistiksel a\u00e7\u0131dan anlaml\u0131 bir fark bulunmad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131. Klinik deney verilerine ili\u015fkin ek analizlerin devam etti\u011fi ifade ediliyor. Klinik ara\u015ft\u0131rmaya Amerika Birle\u015fik Devletleri, Meksika ve Brezilya&#8217;daki 38 \u00e7al\u0131\u015fma b\u00f6lgesinden hafif veya orta \u015fiddette COVID-19&#8217;lu 1231 hasta dahil edilmi\u015fti. Faz 3 PRESECO \u00e7al\u0131\u015fmas\u0131, hafif-orta \u015fiddette semptomlar g\u00f6steren COVID-19 hastalar\u0131nda Avigan\/Reeqonus (favipiravir)&#8217;un erken tedavideki g\u00fcvenli\u011fini ve etkinli\u011fini ara\u015ft\u0131ran \u00e7ift k\u00f6r, plasebo kontroll\u00fc, randomize, [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5219,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5218"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5218"}],"version-history":[{"count":5,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5218\/revisions"}],"predecessor-version":[{"id":5224,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5218\/revisions\/5224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5219"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}